Peptide Cycling & Tolerance: The Basics
Research literature on peptides commonly describes 'cycles' — defined periods of exposure separated by washout intervals — rather than continuous indefinite exposure. This page explains the concept at a reference level.
On this page
Why cycles appear in study designs
Two ideas drive the concept. First, receptor systems under continuous stimulation are described in pharmacology as liable to desensitisation, so intervals are used to limit it. Second, a defined exposure interval followed by a washout interval gives a study a cleaner comparison window than continuous exposure does.
Patterns described in the literature
Published and community references commonly describe blocks such as 8–12 weeks of exposure followed by 4–8 weeks of washout, or a step down to a lower-frequency interval instead of a full washout. These are shapes reported in the literature, not recommendations, and no cycling pattern has been validated for any compound RetaNord supplies.
Material quality and study inputs
Exposure interval is only one variable, and it sits downstream of the one that can actually be verified: what is in the vial. Every RetaNord lot is tested by an independent laboratory by HPLC for purity and mass spectrometry for identity, and ships with a lot-specific Certificate of Analysis — read the CoA.
Frequently asked questions
Do research peptides have to be cycled?
No requirement is established. Cycling appears in study designs and community references as a way to limit receptor desensitisation and to create a clean comparison window, but no cycling pattern has been validated for the compounds RetaNord supplies. Reference information only, not medical advice.
What cycle lengths appear in the literature?
Blocks of roughly 8-12 weeks of exposure followed by 4-8 weeks of washout are the shapes most commonly described. These are reported figures, not recommendations.